Retatrutide: Looking Beyond the Weight-Loss Headlines

Why I’m looking beyond weight loss

When retatrutide comes up, weight loss is usually the first thing people talk about.

And with results above 20%, it’s easy to understand why.

I’ve spent enough of my own life focused on weight — through dieting, fasting and eventually gastric sleeve surgery — to know that the number on the scales is only one part of the story.

I’m interested in what happens around it.

What happens to hunger and food noise? Can people move more easily? What happens to sleep, metabolic health, muscle and everyday quality of life?

And for women navigating midlife, what do we actually know — rather than what are we assuming?

So for our first Peptide Spotlight, I wanted to look beyond the biggest number and see what the retatrutide research actually tells us — and where the evidence stops.

First, what is retatrutide?

Retatrutide is an investigational medicine being developed for obesity and related metabolic conditions.

It works on three hormone receptors: GIP, GLP-1 and glucagon. That’s different from semaglutide — the active ingredient in Ozempic and Wegovy — which targets GLP-1, and tirzepatide, which targets GLP-1 and GIP.

You’ll sometimes hear retatrutide described as a “triple agonist” for this reason.

But there’s something important to understand before we go any further:

Retatrutide is still an investigational medicine.

When we’re talking about results from a retatrutide clinical trial, we’re talking about a defined medicine given at controlled doses, to selected participants, with clinical monitoring.

That research doesn’t tell us that something in a vial labelled “retatrutide” and bought online is the same product.

What happened with weight loss?

The study that first put retatrutide firmly on people’s radar was a Phase 2 trial published in the New England Journal of Medicine in 2023.

The study included 338 adults with obesity or overweight who did not have diabetes.

After 48 weeks, the highest-dose group had lost an average of 24.2% of their starting body weight, compared with 2.1% with placebo.

That’s a significant result.

But 24.2% is a group average, not a prediction of what any individual person will lose.

And while 48 weeks can tell us a lot about whether a treatment works, it can’t answer every question about what happens when people use it for years.

Gastrointestinal side effects were common. Researchers also saw dose-related increases in heart rate, which peaked at around 24 weeks and then declined.

The trial was funded by Eli Lilly.

And now we have Phase 3 evidence

This is one area where the evidence has moved quickly.

TRIUMPH-1 now has a peer-reviewed Phase 3 publication.

That matters because retatrutide is moving beyond the earlier Phase 2 evidence that generated so much attention.

The Phase 3 trial followed adults with obesity without diabetes for 80 weeks and gives us a much larger and longer look at both weight loss and safety.

We’ve covered those results separately because, as always, the headline number isn’t the whole story.

Read our updated TRIUMPH-1 evidence breakdown →

But weight isn’t the only thing researchers are looking at

This is where retatrutide becomes particularly interesting to me.

Researchers have also looked at liver fat, blood glucose, knee pain and obstructive sleep apnoea.

These findings don’t all come from the same study — and that’s important.

We can’t bundle them together and assume that everyone taking retatrutide will experience all of these effects.

But they’re worth looking at individually.

What happened to liver fat?

A smaller randomised substudy involving 98 people looked specifically at liver fat.

At 24 weeks, the highest-dose retatrutide group had an average 82.4% relative reduction in liver fat, compared with a 0.3% increase with placebo.

Changes in liver fat were also associated with improvements in measures related to insulin sensitivity and lipid metabolism.

That’s certainly interesting.

But an 82.4% reduction in liver fat doesn’t mean retatrutide has been shown to reverse liver scarring or prevent liver failure.

Those are much bigger clinical questions.

It’s also worth knowing that this was a relatively small substudy, which limits how confidently we can apply its findings to a much broader population.

What about blood sugar, knee pain and sleep apnoea?

Retatrutide’s Phase 3 programme has looked beyond uncomplicated obesity.

Across different studies, researchers have examined blood glucose in people with type 2 diabetes, knee pain in people with osteoarthritis and breathing disturbances in people with obstructive sleep apnoea.

Some of the reported changes have been substantial.

But there’s a really important point here:

These results come from different groups of people, receiving different doses, across the trial programme, including condition-specific groups within TRIUMPH-1.

We can’t put the best number from each study together and create one imaginary person who loses a huge amount of weight, dramatically improves their blood sugar, stops having knee pain and fixes their sleep apnoea.

That’s not what the evidence shows.

And the knee-pain result is a particularly good example of why wording matters.

Less knee pain doesn’t mean damaged cartilage has been repaired.

Pain could change for several reasons, including reduced body weight and reduced mechanical load on the joint.

The research can tell us that pain changed.

It can’t automatically tell us why.

What about the unexpected things people talk about?

This is an area I’m particularly interested in — partly because of my own experience.

Changes in liver fat, knee pain and sleep apnoea can be measured in clinical research.

That’s very different from someone saying:

“My head feels clearer.”

“I have more energy.”

“I’m not thinking about food all day.”

“I’m less impulsive.”

Or:

“I’m suddenly not interested in alcohol.”

Those experiences can be meaningful.

Sometimes unexpected observations are even what lead researchers to ask new questions.

But a personal experience can’t establish that a medicine caused the change.

Sleep, weight loss, activity, other medicines, expectations and changes in someone’s overall health can all play a part.

I think there’s room for both research and lived experience on Her Own Way. We just need to be really clear about which one we’re talking about.

Why this became personal for me

My own interest in retatrutide goes beyond reading the research.

I started using a product described as retatrutide because of weight. That was the reason I had researched it and the reason I started.

What I wasn’t expecting was the quiet.

For years, food noise had been a constant part of my life — thinking about what I was going to eat, what I shouldn’t eat, what I was craving, whether I should have it and why I couldn’t just be more disciplined.

Then one day I took a tub of ice cream out of the freezer, opened the seal, looked at it — and put it back.

That sounds like such a small thing. For me, it wasn’t.

Before that, if I’d opened the tub, I would have sat there with a spoon and eaten it.

I’d spent decades believing that my struggles with weight came down to willpower. I’d dieted, fasted, had gastric sleeve surgery and lost around 40 kilos — and eventually experienced hunger, cravings and food noise returning.

So suddenly feeling completely uninterested in something I would previously have found difficult to resist made me look at that whole history differently.

I also began noticing things that had nothing obvious to do with weight.

I felt more focused and organised, less impulsive and more emotionally regulated. I felt more productive and like I had more mental space for my kids.

And that raised a lot of questions for me.

But this is where I think the distinction between experience and evidence really matters.

I can’t know from my experience alone what caused those changes.

I also can’t independently confirm that the product I used contained retatrutide.

And my experience certainly isn’t evidence that retatrutide treats ADHD, food noise or any other condition.

What it did was make me curious.

If I was noticing things I hadn’t gone looking for, what were researchers actually finding beyond weight loss?

Which effects had evidence behind them?

Which were being studied?

And which were still simply interesting observations that we couldn’t explain?

That curiosity became part of the reason I created Her Own Way.

Read more about my experience and why I created Her Own Way →

A note about the product I used

I deliberately describe my experience as involving “a product described as retatrutide.”

That’s not just careful wording.

I don’t have independent confirmation of what the product contained, so my experience can’t verify its identity, purity, dose, safety or effectiveness.

That uncertainty matters when we’re talking about an investigational medicine.

A product sold online under the name retatrutide shouldn’t be assumed to be equivalent to the pharmaceutical product being studied in clinical trials.

Where women’s health fits

This is another reason I don’t want the conversation to begin and end with weight.

For many women, weight doesn’t exist in isolation.

It can sit alongside changes in sleep, energy, mobility, blood pressure, blood glucose, migraines, concentration and the enormous hormonal shift that can happen through perimenopause and menopause.

But we need to be careful not to join dots that the research hasn’t joined for us.

These aren’t menopause trials.

The studies don’t establish that retatrutide treats hot flushes, brain fog, ADHD, migraines or addiction.

And they certainly don’t tell us that a metabolic medicine should replace treatment someone already uses for those conditions.

My own history is a good example.

I’ve experienced migraines since my teens, and they improved significantly when I was receiving Botox treatment.

I don’t attribute that improvement to retatrutide simply because migraines are part of my health story.

That’s exactly the kind of distinction I want Her Own Way to keep making.

If a woman loses weight and also notices she sleeps better, moves more easily or feels different generally, that’s worth discussing.

But it doesn’t automatically tell us why the change happened.

What about side effects?

This part belongs beside the exciting results, not buried underneath them.

Gastrointestinal symptoms have been among the most commonly reported side effects in retatrutide trials.

Later Phase 3 reporting has also included altered skin sensations, and some participants have stopped treatment because of adverse events.

As with the weight-loss numbers, those percentages need to be read in the context of the particular trial, dose and analysis rather than treated as a prediction of what will happen to everyone.

And longer studies remain important.

If medicines like retatrutide eventually become treatments people use for years, I want to know much more than what happens over the first few months.

A very different risk: buying “retatrutide” online

There’s another issue here that shouldn’t be confused with the side effects seen in clinical trials.

Products labelled as retatrutide are already being sold outside clinical research.

Australian regulators have warned about unapproved peptide products because they haven’t gone through the same evaluation for quality, safety and effectiveness as approved medicines.

That creates risks the clinical trials can’t measure.

If we don’t know exactly what is in a product, how much is in it, whether it was manufactured correctly or whether it’s sterile, we can’t simply apply the safety data from a pharmaceutical clinical trial to it.

And this isn’t just a theoretical distinction.

It’s also why I’m careful about the way I describe my own experience.

Research into retatrutide isn’t evidence for the safety or effectiveness of every product being sold under its name.

What I still want to know

Retatrutide is one of the treatments I find most interesting to follow because the questions are becoming much bigger than weight loss.

But there is still so much I’d like to know.

What happens to muscle and strength when people lose this much weight?

What happens to food noise over the long term?

How manageable is treatment after several years?

Do improvements in sleep apnoea, mobility and metabolic health continue?

And for women specifically:

Do outcomes change through perimenopause and menopause?

What happens to body composition, bone health and muscle?

Are there meaningful differences in side effects or treatment response between women and men?

And when people report unexpected changes in things like concentration, impulsivity, cravings or alcohol use, are those direct effects, indirect effects of other health changes — or something else entirely?

I don’t want to fill those gaps with assumptions.

I want to see them studied.

Where I land on it

The retatrutide research is genuinely interesting — and the evidence is becoming much more substantial.

The weight-loss results understandably attract attention, but they’re only part of the story.

Changes being studied in liver fat, blood glucose, knee pain and sleep apnoea give us a much broader picture of what researchers are exploring.

And my own experience has made me interested in questions that clinical trials haven’t fully answered yet.

But that doesn’t mean my experience answers them.

A reduction in liver fat isn’t proof of preventing liver disease.

Less knee pain isn’t proof of cartilage repair.

Better metabolic health doesn’t make retatrutide a menopause or ADHD treatment.

And noticing an unexpected change personally doesn’t establish that retatrutide caused it.

For me, that’s what this Peptide Spotlight — and really Her Own Way itself — is about.

Not deciding that an emerging treatment is wonderful or terrible.

Not dismissing women’s experiences because they haven’t been studied yet.

And not turning those experiences into medical claims before the evidence exists.

It’s about following the research as it develops, being honest about what we experience, and keeping the line between the two clear.

Because the questions I’m interested in now go well beyond:

“How much weight can I lose?”

I want to know:

How might my health change? How might my everyday life change? What are the risks? What don’t we understand yet? And are researchers asking enough of the questions that actually matter to women?

Those are the questions I’ll keep following.